- NCIt
- C4969
Loading cancer entity…
Loading cancer entity…
Clinical trials
94 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03131934 | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant(ITREC) | completed | Early Phase 1 | 4 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03407859 | Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL | unknown | Early Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 |
| clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | completed | Early Phase 1 | 3 | Uma BorateOTHER | 1 | Feb 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2026source: clinicaltrials